Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transition to chronic pain: opportunities for novel therapeutics.

ABSTRACT:

SUBMITTER: Price TJ

PROVIDER: S-EPMC6237656 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Transition to chronic pain: opportunities for novel therapeutics.

Price Theodore J TJ Basbaum Allan I AI Bresnahan Jacqueline J Chambers Jan F JF De Koninck Yves Y Edwards Robert R RR Ji Ru-Rong RR Katz Joel J Kavelaars Annemieke A Levine Jon D JD Porter Linda L Schechter Neil N Sluka Kathleen A KA Terman Gregory W GW Wager Tor D TD Yaksh Tony L TL Dworkin Robert H RH

Nature reviews. Neuroscience 20180701 7

PMID: 29765159

Similar Datasets

A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology

Project description:Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. Here, we present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC. OA-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo. To measure the effect of OA-SPARC on neural firing in a scalable format for drug discovery, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell resolution and a throughput of up to 500,000 neurons per day, with patch clamp-like single action potential resolution. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology with different mechanisms of action. We screened ~3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of both functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including well-known ion channel modulators as well as less characterized mechanisms including MEK inhibitors and tyrosine kinase modulators, providing validation of the platform for pain drug discovery.

2023-08-02 | GSE237797 | GEO

Targeting epigenetic mechanisms for chronic visceral pain: A valid approach for the development of novel therapeutics.

Project description: Not available

| S-EPMC7924309 | biostudies-literature

Recombinant dimeric PICK1 protein inhibitors for long-term relief of chronic pain by AAV therapeutics

Project description:Chronic neuropathic pain’s impact, persistence, and limited treatments render it relevant for gene therapy. Here, we describe the development and application of self-assembling dimeric peptide inhibitors of the pain-associated scaffolding protein PICK1 (protein interacting with C-kinase 1) delivered by adeno-associated viral (AAV) vectors. In mice, these peptides prevented mechanical allodynia in inflammatory and neuropathic pain models and reversed neuropathic pain for up to one year. Targeting of somatosensory pain pathways relieved pain without overt side effects, while selective transduction of dorsal root ganglion (DRG) neurons was sufficient for providing pain relief. Using proteomic and phosphoproteomic analysis of DRG tissue, we identified protein kinase C alpha (PRKCA) substrate candidate, that potentially shape this pain-relieving phenotype. We also confirmed PICK1 expression and peptide target engagement in mice and human donor tissue, supporting the potential of AAV-based PICK1 inhibitors as a clinically meaningful strategy for neuropathic pain conditions.

2026-04-10 | PXD073925 | Pride

Recombinant dimeric PICK1 protein inhibitors for long-term relief of chronic pain by AAV therapeutics

2026-04-10 | PXD074049 | Pride

Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.

Project description: Not available

| S-EPMC8701270 | biostudies-literature

A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology.

Project description: Not available

| S-EPMC10950549 | biostudies-literature

Microbial therapeutics: New opportunities for drug delivery.

Project description: Not available

| S-EPMC6504217 | biostudies-literature